A

ACRC Trials | Plano, TX

Research site

(Unclaimed)

Location

5425 W. Spring Creek Parkway, Suite 130, Plano, Texas, United States of America

Site insights

Top conditions

Top treatments

Lorundrostat

Laninamivir Octanoate

Pimecrolimus

Galcanezumab

Lasmiditan

Fesoterodine

Ciclesonide

Glycopyrronium

Diclofenac Sodium Gel

Sisunatovir

Parent organization

This site is a part of ACRC Trials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to...

Active, not recruiting

Hypertension

Drug: Placebo

Drug: lorundrostat Dose 2

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Enrolling

Epstein-Barr Virus Infection

Biological: mRNA-1189

Biological: Placebo

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (Nova 301)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling

Acute Gastroenteritis

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling

COVID-19

SARS-CoV-2 Virus

Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose

Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose